Nevia bio Overview
Nevia Bio is an innovative health technology company committed to transforming women's health through the discovery of biomarkers in vaginal fluid. Our mission is to develop non-invasive, AI-driven diagnostic solutions for early detection of gynecological cancers, with an initial focus on ovarian cancer. By leveraging the world’s largest database of vaginal fluid and multi-omics data, Nevia Bio is pioneering a breakthrough diagnostic platform that has the potential to detect cancers at their earliest and most treatable stages, ultimately improving patient outcomes and reducing treatment costs.
Cumulative Funding Raised Over Time ($)
$3.1MAug 2023
$5.0MMar 2020
$5.0MMar 2022
Latest News
growth-positive
Nevia Bio Completes a $3M Seed Round to Build a Machine Learning-Enabled Platform for Early Detection of Women-Related Diseases
Nevia Bio, a company developing a machine learning empowered platform for early detection of womens health indications, has announced the completion of a $3.1M Seed Round. The funding will be used to support the companys clinical trials in ovarian cancer and to expand its pipeline to additional indications in womens health. Nevia Bios platform decodes information from womens vaginal secretions using machine learning tools to identify specific biomarkers for early detection of diseases. The company has conducted clinical trials and established a biobank of more than 900 samples. Nevia Bio is backed by investors including MindUP Digital Health Incubator, Pitango HealthTech, Alive Israel HealthTech Fund, and the Technion.
Investment
growth-positive
Nevia Bio is using AI to early detect "silent killer" ovarian cancer | CTech
Nevia Bio, formerly known as Gina Life, is a company that aims to democratize preventative medicine and make ovarian cancer screenings accessible to all. Co-founder and CEO Dr. Inbal Zafir-Lavie shared her personal motivation for starting the company, which was the loss of her sister to colorectal cancer. Nevia Bio uses a machine learning model to analyze vaginal secretions for early detection of ovarian cancer, as 75% of women are diagnosed at later stages with poor survival rates. The companys goal is to develop a home-use test that can be ordered online, making it simple and affordable for women to access. Nevia Bio is currently initiating a U.S.-based clinical trial and pursuing FDA approval.
Customers
growth-positive
The FemTech revolution: 7 Israeli companies making headlines in women's health | CTech
The global FemTech market size is expected to grow from $28B in 2021 to $33B in 2022. In Israel, investments in MedTech reached $2.4B in 2021, with FemTech accounting for 6% of the total. The article highlights 7 Israeli FemTech companies making headlines: AiVF, Aquafit, Ginalife, Illumigyn, Ocon Healthcare, Pulsenmore, and Tulipon. These companies are involved in various areas of female health, such as AI-based IVF treatments, intimate gel stick products, early disease detection using AI, gynecology endoscope technology, intrauterine drug delivery, and pregnancy scanning. The companies have received funding from private equity, scientific grants, the Israel Innovation Authority, and various investors. Some companies have also signed distribution agreements and partnerships with global players in the industry. The article emphasizes the growth potential of the FemTech sector and the need for greater recognition.
InvestmentExpand
growth-positive
The femtech duo analyzing discharge to detect female-related diseases
Gina Life, a femtech company co-founded by Dr. Shlomit Yehudai-Reshef and Dr. Inbal Zafir-Lavie, is developing a home-testing kit to detect diseases from endometriosis to cervical cancer using vaginal discharge. The kit, which is expected to be available by 2025, uses a smart pad to provide early diagnosis for a variety of medical conditions. The company has raised over a million dollars in two successful fundraising rounds and recently won the Boston MassChallenge startup accelerator competition. Gina Life is also developing a smartphone app that can analyze the strips on the pad using an artificial intelligence-based algorithm.
InvestmentExpand
growth-positive
Shaping the future of ovarian cancer diagnosis with femtech -
Israeli femtech start-up GinaLife is developing a platform that uses artificial intelligence and data science to detect early signs of problems in womens health. The companys first product is focused on the early detection of ovarian cancer. The test in development analyses vaginal fluids for specific cancer biomarkers. The company has received funding from Israel’s government and is preparing to raise funds for clinical trials in the US and UK. GinaLife is also running a clinical trial for endometriosis and expects to have the first generation of product for ovarian cancer ready in two years.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $5M |
| Last funding | $3.1M |
| Stage | Seed |
| Rounds | 3 |
| Investors | 4 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | www.nevia.bio/ |
Locations
Nahum Het St 7, Haifa, Israel
Photos & Videos
No files yet
Nevia bio Business
Business models
B2B2C, B2B
Product stage
R&D
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & ScreeningDigital HealthcareMedical Decision SupportMedical DevicesMedical MonitorsDiagnostics DevicesTarget Customer
Healthcare & Life SciencesHealthcareProvidersConsumersDemographics & FamilyWomenCore Technology
Artificial IntelligenceMachine LearningTags (13)
artificial-intelligenceearly-detectionpersonalizationdigital-healthcarewomenwomen-healthcancernon-invasivebiomarkersdiagnosticscancer-diagnosticsremote-monitoringfemtechGeographic Markets
GlobalAmericasNevia bio Financials
$5M
Total funding
Undisclosed
Capital raised
$3.1M
Last funding
Seed
Funding stage
3
Total rounds
4
Investors
Cumulative Funding Raised Over Time ($)
$3.1MAug 2023
$5.0MMar 2020
$5.0MMar 2022
Private Equity Funding
Seed
Aug 2023
$3.1M
MindUP (Lead)
,
ALIVE Israel Healthtech Fund, Technion Research & Development Foundation, Pitango HealthTech
Convertible Debt
Mar 2022
Undisclosed
ALIVE Israel Healthtech Fund
Pre-Seed
Mar 2020
$1.9M
MindUP
Nevia bio Lifecycle
Cumulative Funding Raised Over Time
$3.1MAug 2023
$5.0MMar 2020
$5.0MMar 2022
All Events
Seed
Aug 2023
$3.1M
MindUP (Lead)
,
ALIVE Israel Healthtech Fund, Technion Research & Development Foundation, Pitango HealthTech
Convertible Debt
Mar 2022
Undisclosed
ALIVE Israel Healthtech Fund
Pre-Seed
Mar 2020
$1.9M
MindUP
Nevia bio News
5 articles
growth-positive
Nevia Bio Completes a $3M Seed Round to Build a Machine Learning-Enabled Platform for Early Detection of Women-Related Diseases
Nevia Bio, a company developing a machine learning empowered platform for early detection of womens health indications, has announced the completion of a $3.1M Seed Round. The funding will be used to support the companys clinical trials in ovarian cancer and to expand its pipeline to additional indications in womens health. Nevia Bios platform decodes information from womens vaginal secretions using machine learning tools to identify specific biomarkers for early detection of diseases. The company has conducted clinical trials and established a biobank of more than 900 samples. Nevia Bio is backed by investors including MindUP Digital Health Incubator, Pitango HealthTech, Alive Israel HealthTech Fund, and the Technion.
Investment
growth-positive
Nevia Bio is using AI to early detect "silent killer" ovarian cancer | CTech
Nevia Bio, formerly known as Gina Life, is a company that aims to democratize preventative medicine and make ovarian cancer screenings accessible to all. Co-founder and CEO Dr. Inbal Zafir-Lavie shared her personal motivation for starting the company, which was the loss of her sister to colorectal cancer. Nevia Bio uses a machine learning model to analyze vaginal secretions for early detection of ovarian cancer, as 75% of women are diagnosed at later stages with poor survival rates. The companys goal is to develop a home-use test that can be ordered online, making it simple and affordable for women to access. Nevia Bio is currently initiating a U.S.-based clinical trial and pursuing FDA approval.
Customers
growth-positive
The FemTech revolution: 7 Israeli companies making headlines in women's health | CTech
The global FemTech market size is expected to grow from $28B in 2021 to $33B in 2022. In Israel, investments in MedTech reached $2.4B in 2021, with FemTech accounting for 6% of the total. The article highlights 7 Israeli FemTech companies making headlines: AiVF, Aquafit, Ginalife, Illumigyn, Ocon Healthcare, Pulsenmore, and Tulipon. These companies are involved in various areas of female health, such as AI-based IVF treatments, intimate gel stick products, early disease detection using AI, gynecology endoscope technology, intrauterine drug delivery, and pregnancy scanning. The companies have received funding from private equity, scientific grants, the Israel Innovation Authority, and various investors. Some companies have also signed distribution agreements and partnerships with global players in the industry. The article emphasizes the growth potential of the FemTech sector and the need for greater recognition.
InvestmentExpand
growth-positive
The femtech duo analyzing discharge to detect female-related diseases
Gina Life, a femtech company co-founded by Dr. Shlomit Yehudai-Reshef and Dr. Inbal Zafir-Lavie, is developing a home-testing kit to detect diseases from endometriosis to cervical cancer using vaginal discharge. The kit, which is expected to be available by 2025, uses a smart pad to provide early diagnosis for a variety of medical conditions. The company has raised over a million dollars in two successful fundraising rounds and recently won the Boston MassChallenge startup accelerator competition. Gina Life is also developing a smartphone app that can analyze the strips on the pad using an artificial intelligence-based algorithm.
InvestmentExpand
growth-positive
Shaping the future of ovarian cancer diagnosis with femtech -
Israeli femtech start-up GinaLife is developing a platform that uses artificial intelligence and data science to detect early signs of problems in womens health. The companys first product is focused on the early detection of ovarian cancer. The test in development analyses vaginal fluids for specific cancer biomarkers. The company has received funding from Israel’s government and is preparing to raise funds for clinical trials in the US and UK. GinaLife is also running a clinical trial for endometriosis and expects to have the first generation of product for ovarian cancer ready in two years.
InvestmentExpand
Nevia bio Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 14 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 16 classification IDs that could be used for matching.
Nevia bio Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 98/100 |
| Missing | video or image, markets |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 515261261 |
| Crunchbase | gina-life-diagnostics |
| Creator | Shmuel (Sam) Rausnitz |
| Creator email | shmuel.rausnitz@sncentral.org |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-08-31T00:00:00.000Z |
| Created | 2017-01-05T00:00:00.000Z |
| Claimed | Yes |